Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway

Authors: Yanqiong Zhang, Xiaodong Guo, Lu Xiong, Lingxiang Yu, Zhiwei Li, Qiuyan Guo, Zhiyan Li, Boan Li, Na Lin

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

Our previous study identified AKT1, AKT2 and AKT3 as unfavorable prognostic factors for patients with hepatocellular carcinoma (HCC). However, limited data are available on their exact mechanisms in HCC. Since microRNAs (miRNAs) are implicated in various human cancers including HCC, we aimed to screen miRNAs targeting AKTs and investigate their underlying mechanisms in HCC by integrating bioinformatics prediction, network analysis, functional assay and clinical validation.

Methods

Five online programs of miRNA target prediction and RNAhybrid which calculate the minimum free energy (MFE) of the duplex miRNA:mRNA were used to screen optimized miRNA-AKT interactions. Then, miRNA-regulated protein interaction network was constructed and 5 topological features (‘Degree’, ‘Node-betweenness’, ‘Edge-betweenness’, ‘Closeness’ and ‘Modularity’) were analyzed to link candidate miRNA-AKT interactions to oncogenesis and cancer hallmarks. Further systematic experiments were performed to validate the prediction results.

Results

Six optimized miRNA-AKT interactions (miR-149-AKT1, miR-302d-AKT1, miR-184-AKT2, miR-708-AKT2, miR-122-AKT3 and miR-124-AKT3) were obtained by combining the miRNA target prediction and MFE calculation. Then, 103 validated targets for the 6 candidate miRNAs were collected from miRTarBase. According to the enrichment analysis on GO items and KEGG pathways, these validated targets were significantly enriched in many known oncogenic pathways for HCC. In addition, miRNA-regulated protein interaction network were divided into 5 functional modules. Importantly, AKT1 and its interaction with mTOR respectively had the highest node-betweenness and edge-betweenness, implying their bottleneck roles in the network. Further experiments confirmed that miRNA-149 directly targeted AKT1 in HCC by a miRNA luciferase reporter approach. Then, re-expression of miR-149 significantly inhibited HCC cell proliferation and tumorigenicity by regulating AKT1/mTOR pathway. Notably, miR-149 down-regulation in clinical HCC tissues was correlated with tumor aggressiveness and poor prognosis of patients.

Conclusion

This comprehensive analysis identified a list of miRNAs targeting AKTs and revealed their critical roles in HCC malignant progression. Especially, miR-149 may function as a tumor suppressive miRNA and play an important role in inhibiting the HCC tumorigenesis by modulating the AKT/mTOR pathway. Our clinical evidence also highlight the prognostic potential of miR-149 in HCC. The newly identified miR-149/AKT/mTOR axis might be a promising therapeutic target in the prevention and treatment of HCC.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107CrossRefPubMed
2.
Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet. 2012, 379: 1245-1255. 10.1016/S0140-6736(11)61347-0CrossRefPubMed
3.
Sherman M: Recurrence of hepatocellular carcinoma. N Engl J Med. 2008, 359: 2045-2047. 10.1056/NEJMe0807581CrossRefPubMed
4.
Thorgeirsson SS, Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002, 31: 339-346. 10.1038/ng0802-339CrossRefPubMed
5.
Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116: 281-297. 10.1016/S0092-8674(04)00045-5CrossRefPubMed
6.
Han ZB, Zhong L, Teng MJ, Fan JW, Tang HM, Wu JY, Chen HY, Wang ZW, Qiu GQ, Peng ZH: Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol. 2012, 6: 445-457. 10.1016/j.molonc.2012.04.001CrossRefPubMed
7.
Esquela-Kerscher A, Slack FJ: Oncomirs: microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6: 259-269. 10.1038/nrc1840CrossRefPubMed
8.
Wang J, Li J, Shen J, Wang C, Yang L, Zhang X: MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer. 2012, 12: 227- 10.1186/1471-2407-12-227PubMedCentralCrossRefPubMed
9.
10.
Huang YH, Lin KH, Chen HC, Chang ML, Hsu CW, Lai MW, Chen TC, Lee WC, Tseng YH, Yeh CT: Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PLoS One. 2012, 7: e37188- 10.1371/journal.pone.0037188PubMedCentralCrossRefPubMed
11.
Shen G, Rong X, Zhao J, Yang X, Li H, Jiang H, Zhou Q, Ji T, Huang S, Zhang J, Jia H: MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma. Carcinogenesis. 2014, In press,
12.
Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, Zhou X, Gan J: A Serum MicroRNA Panel as Potential Biomarkers for Hepatocellular Carcinoma Related with Hepatitis B Virus. PLoS One. 2014, 9: e107986- 10.1371/journal.pone.0107986PubMedCentralCrossRefPubMed
13.
Zhang Y, Guo X, Xiong L, Kong X, Xu Y, Liu C, Zou L, Li Z, Zhao J, Lin N: MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett. 2012, 586: 4362-4370. 10.1016/j.febslet.2012.10.053CrossRefPubMed
14.
Huang JT, Wang J, Srivastava V, Sen S, Liu SM: MicroRNA Machinery Genes as Novel Biomarkers for Cancer. Front Oncol. 2014, 4: 113-PubMedCentralPubMed
15.
Zhang Y, Guo X, Yang M, Yu L, Li Z, Lin N: Identification of AKT kinases as unfavorable prognostic factors for hepatocellular carcinoma by a combination of expression profile, interaction network analysis and clinical validation. Mol Biosyst. 2014, 10: 215-222. 10.1039/c3mb70400aCrossRefPubMed
16.
Li S, Zhang ZQ, Wu LJ, Zhang XG, Li YD, Wang YY: Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network. IET Syst Biol. 2007, 1: 51-60. 10.1049/iet-syb:20060032CrossRefPubMed
17.
Zhang Y, Li Z, Yang M, Wang D, Yu L, Guo C, Guo X, Lin N: Identification of GRB2 and GAB1 coexpression as an unfavorable prognostic factor for hepatocellular carcinoma by a combination of expression profile and network analysis. PLoS One. 2013, 8: e85170- 10.1371/journal.pone.0085170PubMedCentralCrossRefPubMed
18.
Pan SJ, Zhan SK, Pei BG, Sun QF, Bian LG, Sun BM: MicroRNA-149 inhibits proliferation and invasion of glioma cells via blockade of AKT1 signaling. Int J Immunopathol Pharmacol. 2012, 25: 871-881.PubMed
19.
Lin RJ, Lin YC: Yu AL: miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol Carcinog. 2010, 49: 719-727.PubMed
20.
Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M: The importance of bottlenecks in protein networks: Correlation with gene essentiality and expression dynamics. PLoS Comput Biol. 2007, 3: e59- 10.1371/journal.pcbi.0030059PubMedCentralCrossRefPubMed
21.
Mohamed JS, Hajira A, Pardo PS, Boriek AM: MicroRNA-149 Inhibits PARP-2 and Promotes Mitochondrial Biogenesis via SIRT-1/PGC-1α Network in Skeletal Muscle. Diabetes. 2014, 63: 1546-1559. 10.2337/db13-1364CrossRefPubMed
22.
Chan SH, Huang WC, Chang JW, Chang KJ, Kuo WH, Wang MY, Lin KY, Uen YH, Hou MF, Lin CM, Jang TH, Tu CW, Lee YR, Lee YH, Tien MT, Wang LH: MicroRNA-149 targets GIT1 to suppress integrin signaling and breast cancer metastasis. Oncogene. 2014, 33: 4496-4507. 10.1038/onc.2014.10PubMedCentralCrossRefPubMed
23.
Cheng T, Wang L, Li Y, Huang C, Zeng L, Yang J: Differential microRNA expression in renal cell carcinoma. Oncol Lett. 2013, 6: 769-776.PubMedCentralPubMed
24.
25.
Luo Z, Zhang L, Li Z, Li X, Li G, Yu H, Jiang C, Dai Y, Guo X, Xiang J, Li G: An in silico analysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma. BMC Med Genet. 2012, 19: 3-14.
26.
Jin L, Hu WL, Jiang CC, Wang JX, Han CC, Chu P, Zhang LJ, Thorne RF, Wilmott J, Scolyer RA, Hersey P, Zhang XD, Wu M: MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci. 2011, 108: 15840-15845. 10.1073/pnas.1019312108PubMedCentralCrossRefPubMed
27.
Chen YL, Uen YH, Li CF, Horng KC, Chen LR, Wu WR, Tseng HY, Huang HY, Wu LC, Shiue YL: The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma. Ann Surg Oncol. 2013, 20: 4041-4054. 10.1245/s10434-012-2519-8CrossRefPubMed
28.
Frau M, Ladu S, Calvisi DF, Simile MM, Bonelli P, Daino L, Tomasi ML, Seddaiu MA, Feo F, Pascale RM: Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype. J Hepatol. 2011, 55: 111-119. 10.1016/j.jhep.2010.10.031CrossRefPubMed
29.
Nakajima T, Yasui K, Zen K, Inagaki Y, Fujii H, Minami M, Tanaka S, Taniwaki M, Itoh Y, Arii S, Inazawa J, Okanoue T: Activation of B-Myb by E2F1 in hepatocellular carcinoma. Hepatol Res. 2008, 38: 886-895.PubMed
30.
Wang Y, Zheng X, Zhang Z, Zhou J, Zhao G, Yang J, Xia L, Wang R, Cai X, Hu H, Zhu C, Nie Y, Wu K, Zhang D, Fan D: MicroRNA-149 Inhibits Proliferation and Cell Cycle Progression through the Targeting of ZBTB2 in Human Gastric Cancer. PLoS One. 2012, 7: e41693- 10.1371/journal.pone.0041693PubMedCentralCrossRefPubMed
31.
Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005, 120: 15-20. 10.1016/j.cell.2004.12.035CrossRefPubMed
32.
33.
Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z: A combined computational–experimental approach predicts human microRNA targets. Genes Dev. 2004, 18: 1165-1178. 10.1101/gad.1184704PubMedCentralCrossRefPubMed
34.
35.
Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ: Combinatorial microRNA target predictions. Nat Genet. 2005, 37: 495-500. 10.1038/ng1536CrossRefPubMed
36.
Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R: Fast and effective prediction of microRNA/target duplexes. RNA. 2004, 10: 1507-1517. 10.1261/rna.5248604PubMedCentralCrossRefPubMed
37.
Hsu SD, Tseng YT, Shrestha S, Lin YL, Khaleel A, Chou CH, Chu CF, Huang HY, Lin CM, Ho SY, Jian TY, Lin FM, Chang TH, Weng SL, Liao KW, Liao IE, Liu CC: Huang HD: miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res. 2014, 42 (Database issue): D78-D85.PubMedCentralCrossRefPubMed
38.
Dennis G, Sherman BT, Hosack DA, Yang J, Gao W: DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003, 4: P3- 10.1186/gb-2003-4-5-p3CrossRefPubMed
39.
40.
Chen JY, Mamidipalli S, Huan T: HAPPI: an online database of comprehensive human annotated and predicted protein interactions. BMC Genomics. 2009, 10 (Suppl 1): S16-10.1186/1471-2164-10-S1-S16.PubMedCentralCrossRefPubMed
41.
Matthews L, Gopinath G, Gillespie M, Caudy M, Croft D: Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res. 2009, 37: D619-D622. 10.1093/nar/gkn863PubMedCentralCrossRefPubMed
42.
Brown KR, Jurisica I: Online predicted human interaction database. Bioinformatics. 2005, 21: 2076-2082. 10.1093/bioinformatics/bti273CrossRefPubMed
43.
Aranda B, Achuthan P, Alam-Faruque Y, Armean I, Bridge A: The IntAct molecular interaction database in 2010. Nucleic Acids Res. 2010, 38: D525-D531. 10.1093/nar/gkp878PubMedCentralCrossRefPubMed
44.
Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S: Human Protein Reference Database – 2009 update. Nucleic Acids Res. 2009, 37: D767-D772. 10.1093/nar/gkn892PubMedCentralCrossRefPubMed
45.
Ceol A, Chatr Aryamontri A, Licata L, Peluso D, Briganti L: MINT, the molecular interaction database: 2009 update. Nucleic Acids Res. 2010, 38: D532-D539. 10.1093/nar/gkp983PubMedCentralCrossRefPubMed
46.
Lehne B, Schlitt T: Protein-protein interaction databases: keeping up with growing interactomes. Hum Genomics. 2009, 3: 291-297.PubMedCentralPubMed
47.
Beuming T, Skrabanek L, Niv MY, Mukherjee P, Weinstein H: PDZBase: a protein-protein interaction database for PDZ-domains. Bioinformatics. 2005, 21: 827-828. 10.1093/bioinformatics/bti098CrossRefPubMed
48.
49.
Narayanan T, Gersten M, Subramaniam S, Grama A: Modularity detection in protein-protein interaction networks. BMC Res Notes. 2011, 4: 569- 10.1186/1756-0500-4-569PubMedCentralCrossRefPubMed
50.
Lin ZY, Huang YQ, Zhang YQ, Han ZD, He HC, Ling XH, Fu X, Dai QS, Cai C, Chen JH, Liang YX, Jiang FN, Zhong WD, Wang F, Wu CL: MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1. Int J Cancer. 2014, 135: 541-550. 10.1002/ijc.28707CrossRefPubMed
Metadata
Title
Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway
Authors
Yanqiong Zhang
Xiaodong Guo
Lu Xiong
Lingxiang Yu
Zhiwei Li
Qiuyan Guo
Zhiyan Li
Boan Li
Na Lin
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-253

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

Targeting DNA-PKcs and telomerase in brain tumour cells

Research

Ubiquitin ligase Cbl-b represses IGF-I-induced epithelial mesenchymal transition via ZEB2 and microRNA-200c regulation in gastric cancer cells

Erratum

Erratum To: Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy

Research

Thymoquinone-induced conformational changes of PAK1 interrupt prosurvival MEK-ERK signaling in colorectal cancer

Research

Vasohibin-2 modulates tumor onset in the gastrointestinal tract by normalizing tumor angiogenesis

Research

Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits